At Boston Oncology, we seek to increase access to specialty medications in developing nations and emerging markets by localizing technology and manufacturing capabilities. We do this in two ways.

First, we acquire and manage product licenses and manufacturing processes as part of a world-class portfolio of small-molecule and biotechnology therapies. Second, we establish local factories to deploy this product portfolio across the developing world.

This approach represents a significant departure from the current model, as shown here:

Oncology Drug Development in Emerging Markets